Wyeth’s Torisel clears FDA
This article was originally published in Pharmaceutical Approvals Monthly
Wyeth will launch its advanced kidney cancer treatment Torisel (temsirolimus) in July. FDA approved the novel mTOR inhibitor May 30 for the treatment of renal cell carcinoma. Torisel's main competition is Bayer/Onyx's Nexavar (sorafenib) and Pfizer's Sutent (sunitinib). The Torisel NDA was submitted Oct. 5, 2006, and received a priority review, but the review action date was extended to July 5 after FDA requested additional information. Wyeth has also initiated a trial of temsirolimus in mantle cell lymphoma and is looking at the drug in combination with Nexavar and Sutent...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.